トファシチニブの世界市場機会と戦略

出版:The Business Research Company(TBRC) 出版年月:2024年1月

Tofacitinib Global Market Opportunities And Strategies To 2032

トファシチニブの世界市場:2032年までの市場機会と戦略
Including:
1) By Drug Class: Antirheumatic; Janus kinase inhibitor; Immunosuppressant
2) By Dosage Strength: 5mg; 10mg; 11mg; 22mg
3) By Indication: Ulcerative Colitis; Rheumatoid Arthritis; Psoriasis
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

市場機会と戦略シリーズ(Global Market Opportunities And Strategies)

ページ数244
図表数168
価格 
シングルユーザライセンスUSD 5,000
サイトライセンスUSD 7,500
エンタープライズライセンスUSD 10,000
種別英文調査報告書

お問合せ・ご注文  価格・納期について

Report Description

Tofacitinib Global Market Opportunities And Strategies To 2032 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global tofacitinib market as it emerges from the COVID-19 shut down.

トファシチニブの世界市場機会と戦略

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis

Description:
Where is the largest and fastest growing market for tofacitinib? How does the market relate to the overall economy, demography, and other similar markets? What forces will shape the market going forward? The tofacitinib market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider tofacitinib market; and compares it with other markets.

The report covers the following chapters.

  • Introduction and Market Characteristics
    Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by drug class, by dosage strength, by indication and by distribution channel.
  • Key Trends
    Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
  • Macro-Economic Scenario
    The report provides an analysis of the impact of the Russia-Ukraine war, impact of the COVID-19 pandemic and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the tofacitinib market.
  • Global Market Size and Growth
    Global historic (2017-2022) and forecast (2022-2027, 2032F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional And Country Analysis
    Historic (2017-2022) and forecast (2022-2027, 2032F) market values and growth and market share comparison by region and country.
  • Market Segmentation
    Contains the market values (2017-2022) (2022-2027, 2032F) and analysis for each segment by drug class, by dosage strength, by indication and by distribution channel in the market. Historic (2017-2022) and forecast (2022-2027) and (2027-2032) market values and growth and market share comparison by region market.
  • Regional Market Size and Growth
    Regional market size (2022), historic (2017-2022) and forecast (2022-2027,2032F) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape
    Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Key Mergers and Acquisitions
    Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Market Opportunities And Strategies
    Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations
    This section includes recommendations for tofacitinib providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
  • Appendix
    This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope
Markets Covered:
1) By Drug Class: Antirheumatic; Janus kinase inhibitor; Immunosuppressant
2) By Dosage Strength: 5mg; 10mg; 11mg; 22mg
3) By Indication: Ulcerative Colitis; Rheumatoid Arthritis; Psoriasis; Other Indications
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

Companies Mentioned: Pfizer Inc; Beacon Pharmaceuticals PLC; Pharmascience Inc.; Qilu Pharmaceutical Co., Ltd; Delta Pharma Limited; Drug International Limited; Globe Group

Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; tofacitinib indicators comparison.

Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

TABLE OF CONTENTS

1 Executive Summary
1.1 Tofacitinib – Market Attractiveness And Macro economic Landscape
2 Table Of Contents
3 List Of Tables
4 List Of Figures
5 Report Structure
6 Market Characteristics
6.1 General Market Definition
6.2 Summary
6.3 Tofacitinib Market Definition And Segmentations
6.4 Market Segmentation By Drug Class
6.4.1 Antirheumatic
6.4.2 Janus Kinase Inhibitor
6.4.3 Immunosuppressant
6.5 Market Segmentation By Dosage Strength
6.5.1 5mg
6.5.2 10mg
6.5.3 11mg
6.5.4 22mg
6.6 Market Segmentation By Indication
6.6.1 Ulcerative Colitis
6.6.2 Rheumatoid Arthritis
6.6.3 Psoriasis
6.6.4 Other Indications
6.7 Market Segmentation By Distribution Channel
6.7.1 Hospital Pharmacy
6.7.2 Retail Pharmacy
6.7.3 Online Pharmacy
7 Major Market Trends
7.1 Development Of Advanced Products Such As Tofacitinib Ointment To Treat Rheumatoid Arthritis
7.2 Focus on Getting Approval Of Tofacitinib In New Geographies
7.3 Increase In Generic Drug Launches To Provide Affordable Treatment
8 Tofacitinib Market – Macro Economic Scenario
8.1 COVID-19 Impact On The Tofacitinib Market
8.2 Impact Of The War In Ukraine On The Tofacitinib Market
8.3 Impact Of High Inflation On The Tofacitinib Market
9 Global Market Size and Growth
9.1 Market Size
9.2 Historic Market Growth, 2017 – 2022, Value ($ Million)
9.3 Forecast Market Growth, 2022 – 2027, 2032F Value ($ Million)
9.4 Market Drivers
9.5 Market Restraints
10 Global Tofacitinib Market Segmentation
10.1 Global Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
10.2 Global Tofacitinib Market, Segmentation By Dosage Strength, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
10.3 Global Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
10.4 Global Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
11 Tofacitinib Market, Regional and Country Analysis
11.1 Global Tofacitinib Market, By Region, Historic and Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
11.2 Global Tofacitinib Market, By Country, Historic and Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12 Asia-Pacific Market
12.1 Summary
12.1.1 Market Overview
12.1.2 Region Information
12.1.3 Market Information
12.1.4 Background Information
12.1.5 Government Initiatives
12.1.6 Regulations
12.1.7 Regulatory Bodies
12.1.8 Major Associations
12.1.9 Taxes Levied
12.1.10 Corporate Tax Structure
12.1.11 Investments
12.1.12 Major Companies
12.2 Asia-Pacific Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.3 Asia-Pacific Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.4 Asia-Pacific Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.5 Asia-Pacific Tofacitinib Market: Country Analysis
12.6 China Market
12.7 Summary
12.7.1 Market Overview
12.7.2 Country Information
12.7.3 Market Information
12.7.4 Background Information
12.7.5 Government Initiatives
12.7.6 Regulations
12.7.7 Regulatory Bodies
12.7.8 Major Associations
12.7.9 Taxes Levied
12.7.10 Corporate Tax Structure
12.7.11 Investments
12.7.12 Major Companies
12.8 China Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.9 China Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.10 China Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.11 India Market
12.12 India Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.13 India Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.14 India Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.15 Japan Market
12.16 Japan Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.17 Japan Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.18 Japan Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.19 Australia Market
12.20 Australia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.21 Australia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.22 Australia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.23 Indonesia Market
12.24 Indonesia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.25 Indonesia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.26 Indonesia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.27 South Korea Market
12.28 South Korea Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.29 South Korea Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
12.3 South Korea Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13 Western Europe Market
13.1 Summary
13.1.1 Market Overview
13.1.2 Region Information
13.1.3 Market Information
13.1.4 Background Information
13.1.5 Government Initiatives
13.1.6 Regulations
13.1.7 Regulatory Bodies
13.1.8 Major Associations
13.1.9 Taxes Levied
13.1.10 Corporate tax structure
13.1.11 Investments
13.1.12 Major Companies
13.2 Western Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.3 Western Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.4 Western Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.5 Western Europe Tofacitinib Market: Country Analysis
13.6 UK Market
13.7 UK Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.8 UK Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.9 UK Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.10 Germany Market
13.11 Germany Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.12 Germany Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.13 Germany Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.14 France Market
13.15 France Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.16 France Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
13.17 France Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
14 Eastern Europe Market
14.1 Summary
14.1.1 Market Overview
14.1.2 Region Information
14.1.3 Market Information
14.1.4 Background Information
14.1.5 Government Initiatives
14.1.6 Regulations
14.1.7 Regulatory Bodies
14.1.8 Major Associations
14.1.9 Taxes Levied
14.1.10 Corporate Tax Structure
14.1.11 Investments
14.1.12 Major Companies
14.2 Eastern Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
14.3 Eastern Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
14.4 Eastern Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
14.5 Eastern Europe Tofacitinib Market: Country Analysis
14.6 Russia Market
14.7 Russia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
14.8 Russia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
14.9 Russia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
15 North America Market
15.1 Summary
15.1.1 Market Overview
15.1.2 Region Information
15.1.3 Market Information
15.1.4 Background Information
15.1.5 Government Initiatives
15.1.6 Regulations
15.1.7 Regulatory Bodies
15.1.8 Major Associations
15.1.9 Taxes Levied
15.1.10 Corporate Tax Structure
15.1.11 Investments
15.1.12 Major Companies
15.2 North America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
15.3 North America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
15.4 North America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
15.5 North America Tofacitinib Market: Country Analysis
15.6 USA Market
15.7 Summary
15.7.1 Market Overview
15.7.2 Country Information
15.7.3 Market Information
15.7.4 Background Information
15.7.5 Government Initiatives
15.7.6 Regulations
15.7.7 Regulatory Bodies
15.7.8 Major Associations
15.7.9 Taxes Levied
15.7.10 Corporate Tax Structure
15.7.11 Investments
15.7.12 Major Companies
15.8 USA Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
15.9 USA Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
15.10 USA Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
16 South America Market
16.1 Summary
16.1.1 Market Overview
16.1.2 Region Information
16.1.3 Market Information
16.1.4 Background Information
16.1.5 Government Initiatives
16.1.6 Regulations
16.1.7 Regulatory Bodies
16.1.8 Major Associations
16.1.9 Taxes Levied
16.1.10 Corporate Tax Structure
16.1.11 Investments
16.1.12 Major Companies
16.2 South America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
16.3 South America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
16.4 South America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
16.5 South America Tofacitinib Market: Country Analysis
16.6 Brazil Market
16.7 Brazil Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
16.8 Brazil Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
16.9 Brazil Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
17 Middle East Market
17.1 Summary
17.1.1 Market Overview
17.1.2 Region Information
17.1.3 Market Information
17.1.4 Background Information
17.1.5 Government Initiatives
17.1.6 Regulations
17.1.7 Regulatory Bodies
17.1.8 Major Associations
17.1.9 Taxes Levied
17.1.10 Corporate Tax Structure
17.1.11 Investments
17.1.12 Major Companies
17.2 Middle East Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
17.3 Middle East Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
17.4 Middle East Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
18 Africa Market
18.1 Summary
18.1.1 Market Overview
18.1.2 Region Information
18.1.3 Market Information
18.1.4 Background Information
18.1.5 Government Initiatives
18.1.6 Regulations
18.1.7 Regulatory Bodies
18.1.8 Major Associations
18.1.9 Taxes Levied
18.1.10 Corporate Tax Structure
18.1.11 Major Companies
18.2 Africa Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
18.3 Africa Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
18.4 Africa Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, Value ($ Million)
19 Competitive Landscape and Company Profiles
19.1 Company Profiles
19.2 Pfizer Inc
19.2.1 Company Overview
19.2.2 Products And Services
19.2.3 Business Strategy
19.2.4 Financial Overview
19.3 Beacon Pharmaceuticals PLC
19.3.1 Company Overview
19.3.2 Products And Services
19.3.3 Business Strategy
19.3.4 Financial Overview
19.4 Pharmascience Inc.
19.4.1 Company Overview
19.4.2 Products And Services
19.4.3 Business Strategy
19.4.4 Financial Overview
19.5 Qilu Pharmaceutical Co., Ltd
19.5.1 Company Overview
19.5.2 Products And Services
19.5.3 Business Strategy
19.5.4 Financial Overview
19.6 Delta Pharma Limited
19.6.1 Company Overview
19.6.2 Products And Services
19.6.3 Financial Overview
20 Key Mergers And Acquisitions
20.1 Sun Pharma Acquired Concert Pharmaceuticals
20.2 GSK Acquired Sierra Oncology
20.3 Pfizer Acquired Arena Pharmaceuticals
21 Opportunities And Strategies
21.1 Global Tofacitinib Market In 2027 – Countries Offering Most New Opportunities
21.2 Global Tofacitinib Market In 2027 – Segments Offering Most New Opportunities
21.3 Global Tofacitinib Market In 2027 – Growth Strategies
21.3.1 Market Trend Based Strategies
21.3.2 Competitor Strategies
22 Tofacitinib Market, Conclusions And Recommendations
22.1 Conclusions
22.2 Recommendations
22.2.1 Product
22.2.2 Place
22.2.3 Price
22.2.4 Promotion
22.2.5 People
23 Appendix
23.1 Geographies Covered
23.2 Market Data Sources
23.3 Research Methodology
23.4 Currencies
23.5 The Business Research Company
23.6 Copyright and Disclaimer

List Of Tables

Table 1: Global Tofacitinib Market, Historic, 2017 – 2022, $ Million
Table 2: Global Tofacitinib Market, Forecast, 2022 – 2027, 2032F, $ Million
Table 3: Global Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 4: Global Tofacitinib Market, Segmentation By Dosage Strength, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 5: Global Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 6: Global Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 7: Global Tofacitinib Market, By Region, Historic and Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 8: Global Tofacitinib Market, By Country, Historic and Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 9: Asia-Pacific GDP Per Capita, By Country, 2017-2022, $
Table 10: Asia-Pacific Population, By Country, 2017-2027, Millions
Table 11: Asia-Pacific Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 12: Asia-Pacific Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 13: Asia-Pacific Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 14: China GDP Per Capita, 2017-2022, $
Table 15: China Population, 2017-2027, Millions
Table 16: China Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 17: China Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 18: China Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 19: India Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 20: India Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 21: India Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 22: Japan Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 23: Japan Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 24: Japan Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 25: Australia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 26: Australia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 27: Australia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 28: Indonesia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 29: Indonesia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 30: Indonesia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 31: South Korea Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 32: South Korea Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 33: South Korea Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 34: Western Europe GDP Per Capita, By Country, 2017-2022, $
Table 35: Western Europe Population, By Country, 2017-2027, Millions
Table 36: Western Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 37: Western Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 38: Western Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 39: UK Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 40: UK Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 41: UK Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 42: Germany Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 43: Germany Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 44: Germany Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 45: France Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 46: France Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 47: France Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 48: Eastern Europe GDP Per Capita, By Country, 2017-2022, $
Table 49: Eastern Europe Population, By Country, 2017-2027, Millions
Table 50: Eastern Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 51: Eastern Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 52: Eastern Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 53: Russia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 54: Russia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 55: Russia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 56: North America GDP Per Capita, By Country, 2017-2022, $
Table 57: North America Population, By Country, 2017-2027, Millions
Table 58: North America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 59: North America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 60: North America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 61: USA GDP Per Capita, 2017-2022, $
Table 62: USA Population, 2017-2027, Millions
Table 63: USA Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 64: USA Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 65: USA Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 66: South America GDP Per Capita, By Country, 2017-2022, $
Table 67: South America Population, By Country, 2017-2027, Millions
Table 68: South America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 69: South America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 70: South America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 71: Brazil Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 72: Brazil Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 73: Brazil Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 74: Middle East GDP Per Capita, By Country, 2017-2022, $
Table 75: Middle East Population, By Country, 2017-2027, Millions
Table 76: Middle East Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 77: Middle East Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 78: Middle East Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 79: Africa GDP Per Capita, By Country, 2017-2022, $
Table 80: Asia-Pacific Population, By Country, 2017-2027, Millions
Table 81: Africa Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 82: Africa Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 83: Africa Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Table 84: Global Tofacitinib Market, Key Competitor Estimated Market Shares, 2022, Percentage (%)
Table 85: Pfizer Inc – Financial Overview, 2018 – 2022, $ Billion
Table 86: Beacon Pharmaceuticals PLC – Financial Overview, 2018 – 2022, $ Billion
Table 87: Pharmascience Inc – Financial Overview, 2022, $ Million
Table 88: Qilu Pharmaceutical Co., Ltd – Financial Overview, 2022, $ Million
Table 89: Delta Pharma Limited – Financial Overview, 2018 – 2022, $ Billion
Table 90: Global Tofacitinib Market Size Gain ($ Million), 2022 – 2027, By Country
Table 91: Global Tofacitinib Market Size Gain ($ Million), Segmentation By Drug Class, 2022 – 2027
Table 92: Global Tofacitinib Market Size Gain ($ Million), Segmentation By Dosage Strength, 2022 – 2027
Table 93: Global Tofacitinib Market Size Gain ($ Million), Segmentation By Indication, 2022 – 2027
Table 94: Global Tofacitinib Market Size Gain ($ Million), Segmentation By Distribution Channel, 2022 – 2027
Table 95: Tofacitinib Market Data Sources

List Of Figures

Figure 1: Global Tofacitinib Market Segmentation By Drug Class
Figure 2: Global Tofacitinib Market Segmentation By Dosage Strength
Figure 3: Global Tofacitinib Market Segmentation By Indication
Figure 4: Global Tofacitinib Market Segmentation By Distribution Channel
Figure 5: Global Tofacitinib Market, Historic, 2017 – 2022, $ Million
Figure 6: Global Tofacitinib Market, Forecast, 2022 – 2027, 2032F, $ Million
Figure 7: Global Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 8: Global Tofacitinib Market, Segmentation By Dosage Strength, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 9: Global Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 10: Global Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 11: Global Tofacitinib Market, By Region, Historic and Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 12: Global Tofacitinib Market, By Country, Historic and Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 13: Asia-Pacific Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 14: Asia-Pacific Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 15: Asia-Pacific Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 16: China Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 17: China Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 18: China Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 19: India Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 20: India Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 21: India Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 22: Japan Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 23: Japan Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 24: Japan Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 25: Australia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 26: Australia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 27: Australia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 28: Indonesia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 29: Indonesia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 30: Indonesia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 31: South Korea Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 32: South Korea Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 33: South Korea Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 34: Western Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 35: Western Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 36: Western Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 37: UK Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 38: UK Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 39: UK Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 40: Germany Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 41: Germany Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 42: Germany Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 43: France Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 44: France Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 45: France Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 46: Eastern Europe Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 47: Eastern Europe Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 48: Eastern Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 49: Russia Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 50: Russia Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 51: Russia Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 52: North America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 53: North America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 54: North America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 55: USA Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 56: USA Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 57: USA Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 58: South America Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 59: South America Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 60: South America Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 61: Brazil Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 62: Brazil Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 63: Brazil Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 64: Middle East Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 65: Middle East Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 66: Middle East Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 67: Africa Tofacitinib Market, Segmentation By Drug Class, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 68: Africa Tofacitinib Market, Segmentation By Indication, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 69: Africa Tofacitinib Market, Segmentation By Distribution Channel, Historic And Forecast, 2017 – 2023, 2027F, 2032F, $ Million
Figure 70: Pfizer Inc – Financial Overview, 2018 – 2022, $ Billion
Figure 71: Beacon Pharmaceuticals PLC – Financial Overview, 2018 – 2022, $ Billion
Figure 72: Delta Pharma Limited – Financial Overview, 2018 – 2022, $ Billion
Figure 73: Geographic Regions Covered